photo of

Details

Role Group Leader / Snr Princ Research Fellow
Research area Clinical Sciences

Contact

Available for student supervision
Dr Seal trained as a clinical neuropsychologist and has over 15 years experience in coordinating neuroimaging investigations of brain development. After completing his PhD he was awarded a Wellcome Trust International Fellowship (2001-2002) to support a two-year postdoctoral position in the Section of Neuroimaging, Institute of Psychiatry(IOP), Kings College London. Subsequently, Dr Seal was able to obtain a NARSAD Young Investigator Award (2003-2005) to continue his postdoctoral training in neuroimaging. In 2005 Dr Seal returned to Australia as a member of the Senior Research Group at The Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne. In this position he coordinated several large investigations measuring changes in brain structure and function across the life-span. On the basis of this work he was awarded the Ronald Phillip Griffith Fellowship (2007-2009). From 2007-2010 he successfully coordinated onsite Australia’s largest study investigating the neurocognitive impact of heavy cannabis use on brain development (NHMRC Project 459111).

In 2010 he was was appointed Group Leader of the Developmental Imaging research group at the Murdoch Children's Research Institute. In this role he is responsible for coordinating and facilitating research utilising the Research MRI Scanner and supervises a multidisciplinary team of clinicians, MRI technologists and neuroscientists. He is currently involved in several ongoing studies of neurodevelopment including as Chief Investigator on NHMRC Project Grants and ARC Discovery Grants. He holds a joint appointment (0.5) as a Principal Research Fellow in the Department of Paediatrics, The University of Melbourne
Dr Seal trained as a clinical neuropsychologist and has over 15 years experience in coordinating neuroimaging investigations of brain development. After completing his PhD he was awarded a Wellcome Trust International Fellowship (2001-2002) to support...
Dr Seal trained as a clinical neuropsychologist and has over 15 years experience in coordinating neuroimaging investigations of brain development. After completing his PhD he was awarded a Wellcome Trust International Fellowship (2001-2002) to support a two-year postdoctoral position in the Section of Neuroimaging, Institute of Psychiatry(IOP), Kings College London. Subsequently, Dr Seal was able to obtain a NARSAD Young Investigator Award (2003-2005) to continue his postdoctoral training in neuroimaging. In 2005 Dr Seal returned to Australia as a member of the Senior Research Group at The Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne. In this position he coordinated several large investigations measuring changes in brain structure and function across the life-span. On the basis of this work he was awarded the Ronald Phillip Griffith Fellowship (2007-2009). From 2007-2010 he successfully coordinated onsite Australia’s largest study investigating the neurocognitive impact of heavy cannabis use on brain development (NHMRC Project 459111).

In 2010 he was was appointed Group Leader of the Developmental Imaging research group at the Murdoch Children's Research Institute. In this role he is responsible for coordinating and facilitating research utilising the Research MRI Scanner and supervises a multidisciplinary team of clinicians, MRI technologists and neuroscientists. He is currently involved in several ongoing studies of neurodevelopment including as Chief Investigator on NHMRC Project Grants and ARC Discovery Grants. He holds a joint appointment (0.5) as a Principal Research Fellow in the Department of Paediatrics, The University of Melbourne

Top Publications

  • Atakan, Z, Bhattacharyya, S, Allen, P, Borgwardt, S, Fusar-Poli, P, Martin-Santos, R, Crippa, JA, Seal, M, Kambeitz, JP, Andiappan, M, et al. WHY DOES CANNABIS EFFECT PEOPLE DIFFERENTLY? COMPARING THOSE WITH TEMPORARY PSYCHOTIC SYMPTOMS VS. THOSE WITH NO PSYCHOTIC SYMPTOMS FOLLOWING THE ORAL ADMINISTRATION OF Δ-9-TETRAHYDROCANNABINOL – A FUNCTIONAL MRI STUDY. Schizophrenia Research 117(2-3) : 233 2010
    view publication
  • Valli, I, Stone, JM, Mechelli, A, Bhattacharyya, S, Raffin, M, Poli, PF, Allen, P, Seal, ML, McGuire, PK. ALTERED MEDIAL TEMPORAL ACTIVATION RELATED TO LOCAL GLUTAMATE IN SUBJECTS WITH PRODROMAL SIGNS OF PSYCHOSIS. Schizophrenia Research 117(2-3) : 533 2010
    view publication
  • Testa, RR, Ross, N, Seal, ML, Tonge, B, Pantelis, C. IDENTIFYING THE MARKERS OF MENTAL ILLNESS IN PRIMARY SCHOOL-AGED CHILDREN: A SERIES OF CASE STUDIES EXAMINING COGNITIVE, MOTOR, LANGUAGE AND PSYCHOSOCIAL FACTORS. Schizophrenia Research 117(2-3) : 321 -322 2010
    view publication
  • Fusar-Poli, P, Bhattacharyya, S, Allen, P, Crippa, JA, Borgwardt, S, Martin-Santos, R, Seal, M, O'Carroll, C, Atakan, Z, Zuardi, AW, et al. Effect of image analysis software on neurofunctional activation during processing of emotional human faces.. J Clin Neurosci 17(3) : 311 -314 2010
    view publication
  • Martín-Santos, R, Fagundo, AB, Crippa, JA, Atakan, Z, Bhattacharyya, S, Allen, P, Fusar-Poli, P, Borgwardt, S, Seal, M, Busatto, GF, et al. Neuroimaging in cannabis use: a systematic review of the literature.. Psychol Med 40(3) : 383 -398 2010
    view publication

Page 34 of 43